Regional BioCamp 2013 – insight into the world of the most advanced technology
- Lek, a Sandoz company, once again opened the door to the world of the most advanced technologies to 35 young scientists attending the Regional BioCamp 2013.
- The participants challenged themselves by developing a study case, transferring knowledge into practical work and connecting science and business
- The winners of the Regional BioCamp 2013 Patricia Wildberger and Gašper Pustovrh will participate in the Novartis global BioCamp in Basel in August.
At the conclusion of the third Regional BioCamp, at which Lek, a Sandoz company, once again hosted the 35 most promising science students from the Alpe-Adria region, the winners of the competition part were announced. Patricia Wildberger from the Institute of Biotechnology and Biochemical Engineering at Graz University and Gašper Pustovrh from Biotechnical Faculty at University of Ljubljana developed the best case study and the selected best team included members Božidar Aničić, Katarina Maher, Nejc Rojko, Nadica Sibinovska, Marija Vukomanović, Tina Zupančič and Uroš Zupančič. The members of the winning team received a special acknowledgment for their work, while the individual winners will participate in the Novartis global BioCamp 2013 in Basel, Switzerland.
The theme of all Regional BioCamps is always associated with Sandoz mission which is broadening access to medicines and offering the most advanced therapies to as many patients as possible. This was also a topic of discussion among lecturers and participants of the Regional BioCamp 2013 within the principal theme Contemporary Technologies for Affordable Therapies.
»As a part of one of the leading global pharmaceutical companies we opened the door for three days to promising young experts, for the third year in a row. The Regional BioCamp 2013 offered an insight into the pharmaceutical industry and entrepreneurship in the form of lectures. The participants also showed great interest in viewing the development centers of Sandoz Slovenia and thus getting to know from close up how work is carried out at the highest level of technological innovation and expertise,« explained Dr Darja Ferčej Temeljotov, Head of continuous improvements at Sandoz Development center Slovenia and the president of the organising committee of the Regional BioCamp 2013.
Transferring knowledge into practical work
Besides listening to lectures, the participants of the Regional BioCamp also had an opportunity to actively participate and challenge themselves in team work by developing case studies and applying already acquired knowledge to practical work. The selection of the best two individuals and the best team was based on the participant’s collaboration in a team task involving elaboration and presentation of a case study on the topic of bioinformatics modelling. The participants had to prove themselves not only as science experts but also had to show a great deal of business knowledge.
Dr Mateja Salobir, Head of technical development at Sandoz Biopharmaceuticals Mengeš, a member of the judging panel of the Regional BioCamp 2013, says: »Every year young scientists positively surprise us with their knowledge, inventiveness and potential. They use their curiosity and team work to successfully solve the challenge which is completely new for majority of them – preparing a business plan.«
The third Regional BioCamp in Ljubljana hosted 35 undergraduate and postgraduate students from seven countries: Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Monte Negro, Macedonia and Austria.
The winners will participate in the global BioCamp in Basel
According to the panel’s opinion, when preparing the business plan, the winners of the Regional BioCamp 2013 Patricia Wildberger and Gašper Pustovrh proved themselves to be the best among all participants when combining a scientific and business way of thinking which are both of the utmost importance in order to succeed in pharmacy.
“I really enjoyed these two days in Ljubljana. I gathered very valuable insights and got a unique chance to get a first-hand view of how the pharmaceutical industry works. The key lectures were really interesting and we also learned about challenges pharmaceutical companies face nowadays. I had the pleasure to be part of a really great team, each of our team members brought in their own competence and expertise, so we were able to take on the challenge and prepare a successful business case,” explained Patricia Wildberger.
“The Regional BioCamp was well organized, I really loved it. I must admit I was a little surprised by the win, but I think it was mainly because of our good team work. We all played an equal role in the team and commonly contributed to the success. I’m very enthusiastic about going to Novartis BioCamp, I expect it to be as well organized as the Regional BioCamp in Ljubljana,” said Gašper Pustovrh.
The winners of the Regional BioCamp 2013 will join the participants at the traditional Novartis global BioCamp, which will be held in August in Basel in Switzerland. Together with the top young science experts from all around the globe they will attend a three-day seminar, gaining new knowledge and experience and learning about trends in biotechnology and biopharmacy.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz offers a broad range of about 1, 100 high-quality, affordable products that are no longer protected by patents. With nearly 26,000 employees in approximately 140 countries, Sandoz holds the #1 position globally in biosimilars, injectables, ophthalmics and dermatology as well as a strong global #5 position in inhalables. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion. For more information, please visit www.sandoz.com.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32